In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 10 ( 2022-10-26), p. e0273497-
Abstract:
Transplantoux’s MVT exercise intervention prepares organ transplant recipients to cycle or hike up France’s Mont Ventoux. We aimed to assess (i) MVT’s effects on patient-reported outcomes (PROs) and (ii) perceived barriers and facilitators to physical activity. Methods Using a hybrid design, a convenience sample of transplant recipients participating in MVT (n = 47 cycling (TxCYC); n = 18 hiking (TxHIK)), matched control transplant recipients (TxCON, n = 213), and healthy MVT participants (HCON, n = 91) completed surveys to assess physical activity (IPAQ), health-related quality of life (HRQOL; SF-36 and EuroQol VAS), mental health (GHQ-12), and depressive symptomatology, anxiety, and stress (DASS-21) at baseline, then after 3, 6 (Mont Ventoux climb), 9, and 12 months. TxCYC and TxHIK participated in a 6-month intervention of individualized home-based cycling/hiking exercise and a series of supervised group training sessions. Barriers and facilitators to physical activity (Barriers and Motivators Questionnaire) were measured at 12 months. Results Regarding PROs, except for reducing TxHIK stress levels, MVT induced no substantial intervention effects. For both TxCYC and TxHIK, between-group comparisons at baseline showed that physical activity, HRQOL, mental health, depressive symptomatology and stress were similar to those of HCON. In contrast, compared to TxCYC, TxHIK, and HCON, physical activity, HRQOL and mental health were lower in TxCON. TxCON also reported greater barriers, lower facilitators, and different priority rankings concerning physical activity barriers and facilitators. Conclusion Barely any of the PROs assessed in the present study responded to Transplantoux’s MVT exercise intervention. TxCON reported distinct and unfavorable profiles regarding PROs and barriers and facilitators to physical activity. These findings can assist tailored physical activity intervention development. Trial registration Clinical trial notation: The study was approved by the University Hospitals Leuven’s Institutional Review Board (B322201523602).
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0273497
DOI:
10.1371/journal.pone.0273497.g001
DOI:
10.1371/journal.pone.0273497.g002
DOI:
10.1371/journal.pone.0273497.g003
DOI:
10.1371/journal.pone.0273497.g004
DOI:
10.1371/journal.pone.0273497.g005
DOI:
10.1371/journal.pone.0273497.g006
DOI:
10.1371/journal.pone.0273497.t001
DOI:
10.1371/journal.pone.0273497.t002
DOI:
10.1371/journal.pone.0273497.s001
DOI:
10.1371/journal.pone.0273497.s002
DOI:
10.1371/journal.pone.0273497.s003
DOI:
10.1371/journal.pone.0273497.s004
DOI:
10.1371/journal.pone.0273497.s005
DOI:
10.1371/journal.pone.0273497.s006
DOI:
10.1371/journal.pone.0273497.s007
DOI:
10.1371/journal.pone.0273497.s008
DOI:
10.1371/journal.pone.0273497.s009
DOI:
10.1371/journal.pone.0273497.s010
DOI:
10.1371/journal.pone.0273497.s011
DOI:
10.1371/journal.pone.0273497.r001
DOI:
10.1371/journal.pone.0273497.r002
DOI:
10.1371/journal.pone.0273497.r003
DOI:
10.1371/journal.pone.0273497.r004
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
2267670-3
Permalink